Viemed Healthcare, Inc. (VMD)
Healthcare
- Fundamental
- 4
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore 2 is below the required floor of 3 and 20-day average dollar volume $2.03M is below the $5M liquidity floor; the only chart-consistent long (a pullback/oversold limit toward 8.71–9.00) would also be countertrend — price 9.11 < SMA50 9.28 with MACD -0.09 < 0 and under a declining SMA200 without a reclaim — and no breakout stop qualifies above the 9.35 settled high on a tape this thin.
Company overview
Viemed Healthcare, Inc. provides home medical equipment and post-acute respiratory healthcare services in the U.S. It offers respiratory disease management solutions, including non-invasive ventilation and sleep apnea management, and sells or rents related medical equipment. Founded in 2006, the company is headquartered in Lafayette, Louisiana.
Fundamental
goodViemed Healthcare exhibits strong fundamentals with cash generation, no net debt, and consistent revenue growth.
Solid, cash-generative small-cap: net cash, 20%+ revenue growth, mid-20s earnings multiple, ~6% free-cash-flow yield, no going-concern or covenant issues; margin mix and Medicare concentration are the watch items.
Sentiment
weakSentiment is neutral with no significant catalysts or red flags, and media coverage is split post-earnings.
Q3 2026 earnings (announced, 2026-11-04) is the dominant catalyst and is being received as genuinely split — record revenue of $80.7M (+12.2% y/y) and a reported 2026 revenue-guidance raise against an EPS and slight revenue miss — netting a flat aggregate read (+0.05) with no forward-dated driver behind it. The sentiment delta is determinate but flat (+0.17 baseline → +0.05 scoring), no severe or moderate red flag fired, and the neutral-trailing-only catalyst set with an empty forward calendar keeps the setup in Absent, post-event-digestion territory.
Technical
weakThe stock is in a weak, range-bound state with no clear directional edge.
The chart is a weak, range-bound tape inside a medium-term downtrend: price 9.11 is below the SMA20 (9.53), SMA50 (9.28), SMA200 (9.65), EMA9 (9.24), EMA21 (9.38), WMA9 (9.15), WMA21 (9.42) and DEMA14 (9.17), with MACD line -0.09 below its 0.00 signal and a -0.09 histogram, RSI14 44.1, Williams %R -73.3 and ADX14 17.3 fading from 24.1 — no directional edge in either direction. The only constructive features are a marginal higher low versus the 11-09 8.71 swing (a three-session bounce back to 9.11) and an ATR14 of 0.35 (3.8% of price) that does provide tradable range; price is above only TEMA14 (9.00). Score 2 = mostly neutral-to-weak-bearish, bounce-only. No trade regardless of the score: qualitativeScore 2 < 3 is a hard block, 20-day average dollar volume ~$2.03M is below the $5M liquidity floor, and the only chart-consistent long shape (a pullback/oversold limit) would be countertrend by both clauses (price < SMA50 with macdLine < 0; and price < a declining SMA200 with no momentum reclaim).
You’re looking at 2026-11-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

